Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.5696
- Book/Share 9.1268
- PB 6.1506
- Debt/Equity 2.7512
- CurrentRatio 1.2663
- ROIC 0.1414
- MktCap 113981811982.0
- FreeCF/Share 7.5085
- PFCF 7.4488
- PE 18.8948
- Debt/Assets 0.5268
- DivYield 0.0445
- ROE 0.3465
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BMY | UBS | Neutral | Buy | -- | $65 | Jan. 7, 2026 |
| Upgrade | BMY | BofA Securities | Neutral | Buy | -- | $61 | Dec. 15, 2025 |
| Upgrade | BMY | Guggenheim | Neutral | Buy | -- | $62 | Dec. 12, 2025 |
| Initiation | BMY | Scotiabank | -- | Sector Perform | -- | $45 | Nov. 13, 2025 |
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
Read More
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
Read More
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market, leveraging TRACTr technology for long-term oncology growth. Camzyos delivered 89% YoY revenue growth and promising phase 3 SCOUT-HCM results, supporting potential label expansion to adolescent oHCM patients.
Read More
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Published: January 22, 2026 by: Benzinga
Sentiment: Positive
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Read More
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
Read More
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Read More
2 Buffett Stocks to Load Up On—And 1 to Ditch
Published: January 19, 2026 by: MarketBeat
Sentiment: Negative
Warren Buffett made some substantial changes to the Berkshire Hathaway Inc. NYSE: BRK.B portfolio in the first quarters of 2025, including selling off some $4 billion in Apple Inc. NASDAQ: AAPL shares in order to amass a major cash and Treasuries reserve.
Read More
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Read More
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
Read More
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Read More
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Published: December 24, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive appeal.
Read More
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
Read More
Jenny Harrington's top dividend plays for 2026
Published: December 23, 2025 by: CNBC Television
Sentiment: Neutral
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to share her top dividend plays for 2026.
Read More
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive compensation while awaiting pipeline catalysts.
Read More
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100